

Datasheet: MCA752S

Description:	MOUSE ANTI GUINEA PIG CD8
Specificity:	CD8
Format:	Con S/N
Product Type:	Monoclonal Antibody
Clone:	CT6
Isotype:	IgG1
Quantity:	0.25 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-rad-antibodies.com/protocols.

	Yes	No	Not Determined	Suggested Dilution
Flow Cytometry	■			1/100
Immunohistology - Frozen	■			1/100
Immunohistology - Paraffin			■	
ELISA			■	
Immunoprecipitation			■	
Western Blotting			■	

Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using appropriate negative/positive controls.

Target Species	Guinea Pig
Product Form	Concentrated tissue culture supernatant - liquid
Preservative Stabilisers	0.1% Sodium Azide 0.7% Bovine Serum Albumin
Approx. Protein Concentrations	IgG concentration 1.0 mg/ml
Immunogen	Guinea pig peritoneal T-cells.
Fusion Partners	Spleen cells from immunised BALB/c mice were fused with cells of the X63.Ag8.653 mouse myeloma cell line.
Specificity	Mouse anti Guinea Pig CD8 antibody, clone CT6 reacts with guinea pig CD8 present on cytotoxic T-cells. CD 8 comprises 2 subunits, alpha and beta and exists as either an alpha/alpha homodimer or an alpha/beta heterodimer. Sequence suggests that guinea pig CD8 is more closely related to human than rat or mouse CD8 (Nagarajan et al. 2004).

References

1. Tan, B.T.G. *et al.* (1985) Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. [Hybridoma 4: 115-124.](#)
2. Steerenberg, P.A. *et al.* (1991) Tumour rejection after transfer of line 10 immunity is mediated by two T-cell populations. [Cancer Immunol. Immunother. 34: 103-110.](#)
3. Steerenberg, P.A. *et al.* (1990) Tumour infiltrating leucocytes (tils) during progressive tumour growth and BCG - mediated tumour regression. [Virchows Archiv Cell Pathol. 59: 185-194.](#)
4. Baker, D. *et al.* (1987) Changes in lymphocyte subsets after treatment with cyclophosphamide and during the development of contact sensitivity in the guinea pig. [Int J Immunopharmacol. 9 \(2\): 175-83.](#)
5. Antoniou, A.V. *et al.* (1986) Immunocytochemical identification and quantitation of mononuclear cells in the meninges during the development of chronic relapsing experimental allergic encephalomyelitis (CREAE) in the guinea pig. [Cell Immunol. 97 \(2\): 386-96.](#)
6. Liversidge, J. *et al.* (1987) EAU in the guinea pig: inhibition of cell-mediated immunity and Ia antigen expression by cyclosporin A. [Clin Exp Immunol. 69 \(3\): 591-600.](#)
7. Liversidge, J. & Forrester, J.V. (1988) Experimental autoimmune uveitis (EAU): immunophenotypic analysis of inflammatory cells in chorio retinal lesions. [Curr Eye Res. 7 \(12\): 1231-41.](#)
8. Debout, C. *et al.* (1991) The Kurloff cell in estrogenized guinea pigs as a CT7+ 8BE6- CT6-MR-1- CT10- IgM- lymphocyte with natural killer activity. [Nat Immun Cell Growth Regul. 10 \(6\): 327-35.](#)
9. Shang S *et al.* (2011) Activities of TMC207, rifampin, and pyrazinamide against Mycobacterium tuberculosis infection in guinea pigs. [Antimicrob Agents Chemother. 55 \(1\): 124-31.](#)
10. Lacy HM *et al.* (2011) Essential role for neutrophils in pathogenesis and adaptive immunity in Chlamydia caviae ocular infections. [Infect Immun. 79 \(5\): 1889-97.](#)
11. Komori, T. *et al.* (2011) A Microbial Glycolipid Functions as a New Class of Target Antigen for Delayed-type Hypersensitivity. [J Biol Chem. 286: 16800-6.](#)
12. Hiromatsu, K. *et al.* (2002) Induction of CD1-restricted immune responses in guinea pigs by immunization with mycobacterial lipid antigens. [J Immunol. 169: 330-9.](#)
13. Kramp, J.C. *et al.* (2011) The *in vivo* immunomodulatory effect of recombinant tumour necrosis factor- α in guinea pigs vaccinated with *Mycobacterium bovis* bacille Calmette-Guérin. [Clin Exp Immunol. 165: 110-20.](#)
14. Mishra, N.C. *et al.* (2010) Sulfur mustard induces immune sensitization in hairless guinea pigs. [Int Immunopharmacol. 10: 193-9.](#)
15. Schleiss, M.R. *et al.* (2007) Preconceptual administration of an alphavirus replicon UL83 (pp65 homolog) vaccine induces humoral and cellular immunity and improves pregnancy outcome in the guinea pig model of congenital cytomegalovirus infection. [J Infect Dis. 195: 789-98.](#)
16. Turner, O.C. *et al.* (2003) Immunopathogenesis of pulmonary granulomas in the guinea pig after infection with Mycobacterium tuberculosis. [Infect Immun. 71: 864-71.](#)
17. Wang, Y. *et al.* (2010) Local host response to chlamydial urethral infection in male guinea pigs. [Infect Immun. 78: 1670-81.](#)
18. Yang, H. *et al.* (2011) Three protein cocktails mediate delayed-type hypersensitivity responses indistinguishable from that elicited by purified protein derivative in the guinea pig model of Mycobacterium tuberculosis infection. [Infect Immun. 79: 716-23.](#)
19. Baldwin SL *et al.* (2012) The importance of adjuvant formulation in the development of a tuberculosis vaccine. [J Immunol. 188 \(5\): 2189-97.](#)
20. Obregón-Henao, A. Shang, s. Shanley, C.A. Basaraba, R.J. Caraway, M.L. Duncan, C.G. Ordway, D.J. Orme, I.M. (2013) Cortisone-Forced Reactivation of Weakly Acid Fast Positive Mycobacterium Tuberculosis in Guinea Pigs Previously Treated With Chemotherapy [Mycobacterial Diseases. 2: 116.](#)
21. Xia, J. *et al.* (2014) Virus-specific immune memory at peripheral sites of herpes simplex virus

type 2 (HSV-2) infection in guinea pigs. [PLoS One. 9 \(12\): e114652.](#)

22. Jeevan A *et al.* (2013) Guinea pig skin, a model for epidermal cellular and molecular changes induced by UVR in vivo and in vitro: effects on *Mycobacterium bovis* Bacillus Calmette-Guérin vaccination. [Photochem Photobiol. 89 \(1\): 189-98.](#)

23. Gupta A *et al.* (2012) Protective efficacy of *Mycobacterium indicus pranii* against tuberculosis and underlying local lung immune responses in guinea pig model. [Vaccine. 30 \(43\): 6198-209.](#)

24. Gupta, A. *et al.* (2012) Efficacy of *Mycobacterium indicus pranii* immunotherapy as an adjunct to chemotherapy for tuberculosis and underlying immune responses in the lung. [PLoS One. 7 \(7\): e39215.](#)

Storage

Store at +4°C or at -20°C if preferred.

This product should be stored undiluted.

Storage in frost-free freezers is not recommended. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.

Shelf Life

18 months from date of despatch.

Health And Safety Information

Material Safety Datasheet documentation #10495 available at:
10495: <https://www.bio-rad-antibodies.com/uploads/MSDS/10495.pdf>

Regulatory

For research purposes only

Related Products

Recommended Secondary Antibodies

Goat Anti Mouse IgG (STAR76...)	RPE
Goat Anti Mouse IgG IgA IgM (STAR87...)	Alk. Phos. , HRP
Rabbit Anti Mouse IgG (STAR9...)	FITC
Goat Anti Mouse IgG (STAR77...)	HRP
Rabbit Anti Mouse IgG (STAR12...)	RPE
Goat Anti Mouse IgG (Fc) (STAR120...)	FITC , HRP
Rabbit Anti Mouse IgG (STAR8...)	DyLight®800
Goat Anti Mouse IgG (STAR70...)	FITC
Rabbit Anti Mouse IgG (STAR13...)	HRP
Human Anti Mouse IgG1 (HCA036...)	HRP
Goat Anti Mouse IgG (H/L) (STAR117...)	Alk. Phos. , DyLight®488 , DyLight®549 , DyLight®649 , DyLight®680 , DyLight®800 , FITC , HRP

North & South America

Tel: +1 800 265 7376
Fax: +1 919 878 3751
Email: antibody_sales_us@bio-rad.com

Worldwide

Tel: +44 (0)1865 852 700
Fax: +44 (0)1865 852 739
Email: antibody_sales_uk@bio-rad.com

Europe

Tel: +49 (0) 89 8090 95 21
Fax: +49 (0) 89 8090 95 50
Email: antibody_sales_de@bio-rad.com

'M319233:180719'

Printed on 01 Aug 2018